RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. | Zendy

Mariana Petaccia de Macêdo | Zendy; Fernanda Machado de Melo | Zendy; Júlia da Silva Ribeiro | Zendy; Celso Abdon Lopes de Mello | Zendy; Maria Dirlei Ferreira de Souza Begnami | Zendy; Fernando Augusto Soares | Zendy; Dirce Maria Carraro | Zendy; Isabela Werneck da Cunha | Zendy

Open Access

RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

Author(s) -

Mariana Petaccia de Macêdo,

Fernanda Machado de Melo,

Júlia da Silva Ribeiro,

Celso Abdon Lopes de Mello,

Maria Dirlei Ferreira de Souza Begnami,

Fernando Augusto Soares,

Dirce Maria Carraro,

Isabela Werneck da Cunha

Publication year - 2015

Publication title -

oncoscience

Language(s) - English

Resource type - Journals

ISSN - 2331-4737

DOI - 10.18632/oncoscience.118

Subject(s) - neuroblastoma ras viral oncogene homolog , kras , colorectal cancer , medicine , mutation , primary tumor , metastasis , oncology , cancer , metastatic lesion , cancer research , pathology , gene , biology , genetics

Mutations in KRAS and NRAS genes are negative predictors of anti-EGFR therapies response in metastatic colorectal cancer. There are few reports on RAS testing in synchronous primary colorectal cancer (SP-CRC) and a lack of recommendations on which tissue should be tested for the mutation in this disease. This study analyzed the RAS status of both lesions in SP-CRC patients and in their metastasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research